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Background: Since reduction annuloplasty alone for ischemic mitral regurgitation (MR) cannot prevent late
recurrence of MR or improve survival for those with left ventricular (LV) dysfunction, and the surgical approach to
this etiology is still controversial, we conducted a study to assess the efficacy of the additional papillary muscle
approximation (PMA) procedure for ischemic MR by comparing the different subtypes of PMA.
Methods: We studied 45 patients who underwent mitral annuloplasty and papillary muscle approximation
(PMA) for ischemic MR between 2003 and 2012. Papillary muscles were approximated entirely (cPMA: complete
PMA, n = 32) through an LV incision or partially from the tips to mid-parts (iPMA: incomplete PMA, n = 13) through
the mitral and aortic valves. Twenty-three patients with cPMA also underwent LV plasty (LVP). We assessed the
outcomes after PMA by comparing cPMA and iPMA.
Results: The baseline MR grade, NYHA class, LV end-diastolic diameter, and LV ejection fraction (LVEF) were
2.8 ± 1.0, 3.2 ± 0.6, 67 ± 6 mm, and 30 ± 10%, respectively. There were no significant differences in these parameters
among those with iPMA, cPMA/LVP-, and cPMA/LVP+, though iPMA patients had better LVEF than others. Three
patients died before discharge and 12 died during the follow-up. Recurrence of grade 2+ and 3+ MR occurred in
8 and 2 patients, respectively. Reoperation for recurrent MR was performed only for the 2 patients with recurrence
of grade 3+ MR. The cPMA was associated with lower mortality (log-rank P = 0.020) and a lower rate of recurrence
of MR ≥2+ (log-rank P = 0.005) than iPMA. In contrast, there were no significant differences in the mortality (log-rank
P = 0.45) and rate of recurrence (log-rank P = 0.98) between those with cPMA/LVP- and cPMA/LVP+. The 4-year
survival rate and rate of freedom from recurrence of MR ≥2+ were 83% and 85% for those with cPMA, repectively.
In contrast, the rates were 48% and 48% for those with iPMA, respectively.
Conclusions: Complete PMA could be associated with lower postoperative mortality and higher durability of mitral
valve repair for ischemic MR.
Keywords: Cardiomyopathy, Ischemic heart disease, Mitral valve, SurgeryBackground
Ischemic mitral regurgitation (MR) is a predictor of
mortality in patients with ischemic heart failure [1].
This disease is predominantly caused by left ventricular
(LV) remodeling and subsequent displacement of the
papillary muscles [2], usually without structural valve
lesions [3]. The displacement of the papillary muscles* Correspondence: ymatsui@med.hokudai.ac.jp
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unless otherwise stated.results in tethering of the mitral valve that is associated
with increased stiffness of the mitral valve leaflet and
loss of the normal leaflet opening and closure [4]. Since
Bolling and Bach first reported the efficacy of reduction
annuloplasty [5], this procedure has been the gold
standard of surgical treatment for ischemic MR. How-
ever, annuloplasty alone cannot provide a survival bene-
fit for those with LV dysfunction [6], and is associated
with a high prevalence of late recurrence of MR [7],
which is an important predictor of mortality after sur-
gery for ischemic MR [8]. Reduction annuloplasty mayLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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shift of the posterior annulus by the ring and result in re-
currence of MR late after the annuloplasty [9]. Thus, the
mitral valve procedure alone could be insufficient to treat
ischemic MR because this is a ventricular disease rather
than a valvular disease, and additional ventricular and sub-
mitral procedures could be beneficial. We adopted a sub-
mitral procedure named papillary muscle approximation
(PMA) as a radical procedure for ischemic MR with severe
LV dysfunction. In this procedure, we approximate the
papillary muscles entirely or partially depending on the
patient’s condition. We hypothesized that PMA could im-
prove the survival and durability of mitral valve repair and
the extent of approximation could affect the outcomes.
We assessed the efficacy of this procedure by comparing
the different subtypes of PMA.
Methods
Study design
Between 2003 and 2012, papillary muscle approximation
was performed for 127 patients with functional MR, of
whom 70 underwent this procedure for ischemic MR.
Among them, 45 patients were studied after exclusion of
25 patients due to the following reasons: lack of follow-up
echocardiographic data (n = 16), PMA performed as reop-
eration (n = 3), with a concomitant left ventricular assist
device (n = 1), with another leaflet procedure (n = 1) or
posterior left ventricuoplasty (n = 5). All data were col-
lected retrospectively from medical records and our data-
base. The study protocol was approved by the Institutional
Review Board of the Hokkaido University Hospital for
Clinical Research.
Examinations of cardiac parameters
Echocardiography was performed within 1 week before
surgery and repeated before discharge at 0.9 ± 0.7 months
(range, 0.2 to 4.2 months) after surgery. After discharge,
follow-up echocardiography was performed regularly on
an outpatient basis. The latest echocardiographic study
was performed at a mean follow-up time of 2.6 ± 2.2 years.
The following cardiac parameters were acquired: LV end-
diastolic diameter, LV end-systolic diameter, LV ejection
fraction (LVEF), MR grade, deceleration time, coaptation
height of the mitral valve, and interpapillary muscle dis-
tance. The LV end-diastolic and end-systolic diameters
were measured by M-mode transthoracic echocardiog-
raphy. The LVEF was calculated by the modified Simpson
method. The severity of MR was graded based on color
Doppler images as follows: 1+, mild; 2+, moderate; 3+,
moderately severe; and 4+, severe [10]. The deceleration
time of the early transmitral flow velocity was measured
on an apical long-axis color Doppler flow image. The
coaptation height of the mitral valve was measured in 2-
and 4-chamber apical views in mid-systole by B-modetransthoracic echocardiography [11]. The interpapillary
muscle distance was also measured in the short axis view
at the papillary muscle level in end-diastole [12]. Mitral
valve tethering was defined as significant if the coaptation
height of the mitral valve was ≥10 mm or interpapillary
muscle distance was ≥30 mm. The LV end-systolic volume
was evaluated in 40 (89%) patients using echocardiography
(N = 12, 30%), quantitative gated scintigraphy (N = 17,
43%), magnetic resonance imaging (N = 2, 5%) and left
ventriculography (N = 9, 22%).
Operative procedures
All the procedures were performed through a median ster-
notomy. Cardiopulmonary bypass was commenced through
the ascending aorta and both vena cavae. After aortic cross
clamping, blood cardioplegia was administrated and cardiac
arrest was obtained. Subsequent procedures were per-
formed under moderate hypothermia. Mitral annuloplasty
was performed for all the patients who were indicated for
PMA. We used a true-sized semi-rigid (Physioring or Phy-
sioring II, Edwards Lifesciences, Irvine, CA, USA) or rigid
(Rigid Saddle Annuloplasty Ring, St. Jude Medical, Inc., St
Paul, MN, USA) annuloplasty ring. The patients with sig-
nificant mitral valve tethering underwent PMA, which we
adopted to correct tethering by gathering the papillary
muscles that were displaced due to LV remodeling. The
details of the procedure were described elsewhere [13].
The papillary muscles were entirely approximated side-by-
side (complete PMA) through an LV incision or partially
from the tips to the mid-parts (incomplete PMA) through
the mitral or aortic valve using pledgetted mattress sutures
of 3–0 polypropylene (Figure 1). The method was selected
based on the presence of a myocardial scar lesion on the
anterior LV wall. If one existed, an LV incision was made
on the anterior LV wall and complete PMA was per-
formed. Otherwise, incomplete PMA without an LV inci-
sion was performed because entire approximation through
the cardiac valves is technically difficult, especially at the
bases of papillary muscles. The presence of a myocardial
scar was evaluated preoperatively using quantitative gated
scintigraphy, positron emission tomography, or magnetic
resonance imaging. The LV was closed after complete
PMA with direct suturing or concomitant left ventriculo-
plasty (LVP), if indicated.
The patients with severe LV dilatation (end-diastolic
diameter ≥65 mm) and a broad anterior myocardial scar
underwent overlapping left ventriculoplasty, which was
developed as a radical procedure to reduce the LV vol-
ume and restore the LV shape and function. The details
of the procedure were described elsewhere [14]. Papillary
muscle suspension was adopted from 2005 to reinforce
the effect of PMA by suspending the approximated tips
of the papillary muscles to the mitral annulus using 4–0
polytetrafluoroethylene sutures. Initially, the suspension
Figure 1 Schematic of complete and incomplete papillary muscle approximation procedures.
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apical tethering, though anterior suspension became pre-
dominant from 2008, aiming at reduction of posterior
tethering. Coronary artery bypass grafting was performed
if the patient had untreated and significant coronary le-
sions. The Maze procedure and tricuspid annuloplasty
were performed when needed. Tricuspid annuloplasty was
indicated even for mild regurgitation if the patients had se-
verely deteriorated LV function or pulmonary hyperten-
sion. Perioperative hemodynamic instability refractory to
medical control was treated with percutaneous cardiopul-
monary support and intraaortic balloon pumping.
Statistical analyses
Continuous variables are expressed as mean ± standard
deviation and categorical variables as numbers and per-
centages. Preoperative and postoperative data were com-
pared using the Wilcoxon signed-rank test. Comparisons
among 3 groups were conducted using the Kruskal-Wallis
test for continuous data. Post hoc tests were performed
using the Mann–Whitney U test with Bonferroni’s correc-
tion. Categorical data were compared using the chi-square
test or Fisher’s exact test, if appropriate. Postoperative
mortality and freedom from recurrence of MR were esti-
mated using the Kaplan–Meier method, and differences
among groups were assessed by the log-rank test. A two-
sided P value <0.05 was considered to indicate statistical
significance in all the tests. All analyses were performed




Table 1 shows the patients’ baseline characteristics. The
mean age of the study subjects was 62 ± 12 (range, 32 to
85) years and 38 (84%) were male. The baseline New YorkHeart Association (NYHA) functional class was III/IV for
39 (87%) patients. Complete PMA without LVP was asso-
ciated with younger age. Coronary artery lesions and the
severity of heart failure did not significantly differ among
the 3 groups.
Surgical procedures
Table 2 summarizes the operative procedures. Mitral
annuloplasty was perforemed for all the patients. Complete
and incomplete PMA were performed for 32 (71%) and 13
(29%) patients, respectively. Twenty-three (72%) of those
with complete PMA underwent concomitant LVP. All the
patients with LVP underwent overlappling left ventriculo-
plasty. Papillary muscle suspension was performed for 24
(53%) patients. Anterior and posterior suspension were
performed for 14 and 8 patients, respectively. Coronary ar-
tery bypass was performed for 41 (91%) patients.
Cardiac sizs and function
Table 3 summarizes the perioperative cardiac sizes and
functions. The baseline LV size, MR grade, and severity of
mitral valve tethering did not significantly differ among
the 3 groups. However, incomplete PMA was associated
with better baseline LVEF. Postoperatively, the LV size,
MR grade, coaptation height, and interpapillary muscle
distance decreased significantly for all 3 groups. The LVEF
significantly increased for those with complete PMA,
though there was no significant change in LVEF for those
with incomplete PMA (Figure 2). These postoperative pa-
rameters did not significantly differ among the 3 groups.
Postoperative mortality
Three patients died before discharge and 12 died during
a mean follow-up time of 3.5 ± 2.3 years. Cardiac-related
deaths were observed for 3, 1, and 4 patients, respect-
ively (P = 0.78). Other non-cardiac causes of death were
Table 1 Patients’ baseline characteristics
Incomplete PMA Complete PMA P
Value(N = 13) LVP-(N = 9) LVP + (N = 23)
Age, years 65 ± 8 50 ± 14 65 ± 10 0.024
Male, n (%) 11 (85%) 9 (100%) 18 (78%) 0.48
Hypertension, n (%) 8 (62%) 4 (44%) 7 (30%) 0.19
Dialysis, n (%) 2 (15%) 2 (22%) 2 (9%) 0.62
Diabetes, n (%) 7 (54%) 4 (44%) 10 (44%) 0.92
Atrial fibrillation, n (%) 2 (15%) 0 4 (17%) 0.53
History of VT, n (%) 0 1 (11%) 5 (22%) 0.21
Coronary lesions, n (%)
Left anterior descending 12 (92%) 8 (89%) 23 (100%) 0.23
Left circumflex 12 (92%) 8 (89%) 16 (70%) 0.26
Right 13 (100%) 7 (78%) 18 (78%) 0.13
NYHA class, n (%) 0.43
II 3 (23%) 2 (22%) 1 (4%)
III 6 (46%) 5 (56%) 14 (61%)
IV 4 (31%) 2 (22%) 8 (35%)
Inotrope, n (%) 2 (15%) 1 (11%) 3 (13%) 1.0
Urgent, n (%) 2 (15%) 0 2 (9%) 0.65
IABP, n (%) 2 (15%) 0 6 (26%) 0.26
PCPS, n (%) 0 0 1 (4%) 1.0
PMA = papillary muscle approximation, LVP = left ventriculoplasty, VT = ventricular tachyarrhythmia, NYHA = New York Heart Association, IABP = intraaortic balloon
pumping, PCPS = percutaneous cardiopulmonary support.
Table 2 Operative procedures
Incomplete PMA Complete PMA P Value
(N = 13) LVP-(N = 9) LVP + (N = 23)
Mitral annuloplasty, n (%) 13 (100%) 9 (100%) 23 (100%) N/A
Ring size, n (%) 0.30
24 mm 0 0 1 (4%)
26 mm 6 (46%) 6 (67%) 17 (74%)
28 mm 6 (46%) 3 (33%) 3 (13%)
30 mm 1 (8%) 0 2 (9%)
PMA, n (%) <0.001
Complete PMA 0 9 (100%) 23 (100%)
Incomplete PMA 13 (100%) 0 0
PM suspension, n (%) 0.29
None 5 (39%) 3 (33%) 15 (65%)
Anterior 6 (46%) 3 (33%) 5 (22%)
Posterior 2 (15%) 3 (33%) 3 (13%)
Overlapping left ventriculoplasty, n (%) 0 0 23 (100%) <0.001
CABG, n (%) 13 (100%) 8 (89%) 20 (87%) 0.41
TAP, n (%) 9 (75%) 4 (44%) 17 (74%) 0.34
Maze, n (%) 1 (8%) 0 2 (9%) 1.0
PMA = papillary muscle approximation, LVP = left ventriculoplasty, PM = papillary muscles, CABG = coronary artery bypass grafting, AVR = aortic valve replacement,
TAP = tricuspid annuloplasty, AVR = aortic valve replacement.
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A vs. B A vs. C B vs. C
Preoperative values
LVDd, mm 66±5 65±5 68±7 1.0 1.0 0.64
LVDs, mm 55±7 57±6 58±8 1.0 0.42 1.0
LVESVI, ml/m2 95±24 112±26 117±46 0.74 0.50 1.0
LVEF, % 35±9 28±4 27±10 0.05 0.039 0.84
MR grade 2.8±1.0 2.9±1.1 2.8±1.1 1.0 1.0 1.0
DCT, ms 208±71 159±47 151±44 0.39 0.09 1.0
IPMD, mm 31±7 28±4 29±5 0.71 1.0 1.0
CH (2CV), mm 11±2 9±2 10±2 0.26 0.24 1.0
CH (4CV), mm 9±2 10±3 10±2 1.0 1.0 1.0
Postoperative values
LVDd, mm 57±6** 58±4** 63±8** 1.0 0.06 0.23
LVDs, mm 48±7** 48±6** 51±11** 1.0 0.35 0.61
LVESVI, ml/m2 64±14** 78±25* 70±26** 0.90 1.0 1.0
LVEF, % 34±10 33±7* 39±14** 1.0 0.78 0.85
MR grade 0.4±0.5** 0.3±0.4** 0.4±0.7** 1.0 1.0 1.0
DCT, ms 274±61* 205±70 207±60* 0.25 0.06 1.0
IPMD, mm 10±7** 7±7* 5±6** 1.0 0.32 1.0
CH (2CV), mm 5±3* 4±3* 3±3** 1.0 1.0 1.0
CH (4CV), mm 4±3** 4±2* 4±3** 1.0 1.0 1.0
PMA = papillary muscle approximation, LVP = left ventriculoplasty, LV = left ventricle, LVDd = LV end-diastolic diameter, LVEF = LV ejection fraction, LVESVI = LV
end-systolic volume index, MR = mitral regurgitation, DCT = deceleration time, IPMD = interpapillary muscle distance, CH = coaptation height of the mitral valve,
2CV = 2-chamber apical view, 4CV = 4-chamber apical view.
†Bonferroni corrected P.
*P <0.05 or **P<0.01 compared with preoperative values.
Figure 2 Comparison of pre- and postoperative LVEF among
those with iPMA, cPMA/LVP-, and cPMA/LVP+. cPMA = complete
papillary muscle approximation, iPMA = incomplete PMA, LVEF = left
ventricular ejection fraction, LVP = left ventriculoplasty. *P < 0.05
compared with preoperative value.
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suicide for 1. Hospital mortality rates were 15%, 0%, and
4.3% for those with incomplete PMA, complete PMA/
LVP-, and complete PMA/LVP+, respectively (P = 0.42).
The postoperative mortality was significantly different be-
tween those with complete and incomplete PMA (log-rank
P = 0.020, Figure 3A). The 1-, 2-, and 4-year survival rates
were 90%, 87%, and 83% for those with complete PMA, re-
spectively. In contrast, those rates were 83%, 75%, and 48%
for those with incomplete PMA, respectively. Concomitant
LVP and papillary muscle suspension did not affect mor-
tality. There was no significant difference in mortality
between those with complete PMA/LVP+ and complete
PMA/LVP- (log-rank P = 0.45, Figure 3B) or among those
with anterior papillary muscle suspension, posterior sus-
pension, and without suspension (log-rank P = 0.48).
The postoperative NYHA functional class was class II
or less in all but 3 patients with class III and did not sig-
nificantly differ among the 3 groups (P = 0.76). At the
latest follow-up, most (88%) of the patients had NYHA
functional class II or less.
Figure 3 Comparison of survival between complete and incomplete papillary muscle approximation procedures (A), and complete
papillary muscle approximation with and without left ventriculoplasty (B). cPMA = complete papillary muscle approximation, iPMA = incomplete
PMA, LVP = left ventriculoplasty.
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Recurrence of MR ≥2+ was observed in 10 patients, of
whom only 2 had grade 3+. No patient had grade 4+ re-
currence. Reoperation for recurrent MR was performed
for the 2 patients with recurrence of grade 3+ MR. One
had incomplete PMA and presented recurrent MR due
to infective endocarditis and underwent mitral valve re-
placement with redo PMA 2 months after the initial op-
eration. The other had early postoperative recurrence of
MR after complete PMA due to dehiscence of the PMA
sutures. He underwent redo PMA but died before dis-
charge due to mediastinitis 17 months after the initial
operation. Kaplan-Meier curves for the rate of recurrence
of MR significantly differed between those with complete
and incomplete PMA (log-rank P = 0.005, Figure 4A). The
1-, 2-, and 4-year rates of freedom from recurrence wereFigure 4 Comparison of freedom from recurrence between complete
and complete papillary muscle approximation with and without left ven
iPMA = incomplete PMA, LVP = left ventriculoplasty.93%, 85%, and 85% for those with complete PMA, respect-
ively. In contrast, those rates were 57%, 48%, and 48% for
those with incomplete PMA, respectively. Concomitant
LVP and papillary muscle suspension did not affect the
durability of the mitral valve repair. The rates of freedom
from recurrence did not significantly differ between
those with complete PMA/LVP- and complete PMA/
LVP + (log-rank P = 0.98, Figure 4B) or among those
with different types of papillary muscle suspension (log-
rank P = 0.43).
Discussion
In this study, we assessed the results of PMA for ische-
mic MR and demonstrated that mitral valve repair with
complete PMA was associated with a satisfactorily high
postoperative survival rate and durability of repairand incomplete papillary muscle approximation procedures (A)
triculoplasty (B). cPMA = complete papillary muscle approximation,
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in previous reports. In addition, the extent of approxi-
mation affected the outcomes. The approximation of
the entire papillary muscles was associated with better
outcomes than that partially from the tips to mid-parts
of the papillary muscles.
The indication for mitral valve repair of ischemic MR
still remains controversial because its benefit has not been
proven. Wu et al. reported that mitral annuloplasty pro-
vided no significant survival benefit for those with moder-
ate to severe MR and LV dysfunction [6]. In contrast, a
recent subanalysis of the STICH trial showed that adding
mitral valve repair to CABG could be beneficial for those
with LV dysfunction and moderate to severe MR com-
pared with CABG alone or medical treatment alone [15].
However, even with mitral valve repair, postoperative mor-
tality is still high in this clinical setting. The 5-year mortal-
ity rates were 41%, 54%, and 55% for those with mitral
valve repair with CABG, CABG alone, and medication
alone, respectively. Mitral valve repair with reduction
annuloplasty alone for ischemic MR frequently results in
late recurrence of MR. The reported rates of recurrence
are between 15% and 25% within 6 months and appro-
ximately 70% at 5 years [7]. The issue of durability of the
repair may be critical because recurrence of MR is associ-
ated with mortality [8]. However, it remains a matter of
debate whether mitral valve replacement rather than re-
pair should be selected to prevent recurrence. A recent
study demonstrated that there was no significant differ-
ence in postoperative survival between mitral valve repair
and replacement, though reoperation is frequently associ-
ated with repair due to recurrence [16]. In contrast, De
Bonis et al. reported that mitral valve repair was preferable
to replacement in terms of postoperative survival and
improvement of cardiac functions [17]. Thus, reduction
annuloplasty alone is not always a suitable surgical option
for ischemic MR in terms of the mortality and recurrence
of MR, though mitral valve replacement cannot provide a
further benefit. The severity of LV remodeling may have a
great impact on the results because ischemic MR is a ven-
tricular disease rather than a simple valvular disease. In-
deed, a dilated LV (≥65 mm) is associated with poor
outcomes after reduction annuloplasty for ischemic MR
[18]. Therefore, an additional procedure such as a ven-
tricular or submitral one, could be required for improve-
ment of the outcomes.
We have adopted papillary muscle approximation to
correct mitral valve tethering for functional MR since
2003 [13]. In this procedure, the outward tethering is
directly corrected by gathering the papillary muscles to-
gether. Apical and posterior tethering can also be im-
proved because the LV dimension decreases due to
inward traction of the LV wall by the approximated pap-
illary muscles. Those corrections of tethering may resultin a reduction of leaflet tension and restoration of nor-
mal leaflet motion. Therefore, we adapt a true-sized
annuloplasty ring for mitral valve repair with PMA be-
cause a downsized annuloplasty ring may not be neces-
sary after the correction of mitral valve tethering. The
use of a true-sized ring might also prevent functional
mitral stenosis that could occur after reduction annulo-
plasty [19].
There are two different types of PMA in terms of the ex-
tent of approximation: complete and incomplete PMA. Al-
though procedures similar to both complete [20,21] and
incomplete [22] PMA have been proposed, the appropriate
concept for this procedure remains unestablished. In this
study, we demonstrated that complete PMA was associated
with lower mortality and higher durability of repair than
incomplete PMA. This is consistent with the report by
Jensen et al. They proposed that the traction of the basal
papillary muscle was preferable to traction of the papillary
muscle tip because instability of the LV wall attached by
the papillary muscles might permit LV remodeling and re-
sult in recurrence of MR [23]. The inferoposterior LV wall
function could play an important role in the treatment of
functional MR. Regional remodeling including posterome-
dial papillary muscles after inferior myocardial infarction
causes ischemic MR with a smaller degree of LV dilatation
and dysfunction than anterior infarction [24]. In addition,
Pocar et al. reported that impaired regional inferoposterior
wall motion was a predictor of the recurrence of MR after
reduction annulopalsty in patients with ischemic MR [25].
Complete PMA causes regional surgical reverse remodel-
ing at the inferoposterior LV wall and stabilizes the LV wall
at the base of the papillary muscles as after papillary
muscle imbrication [26]. This could explain why complete
PMA was associated with significant improvement of LVEF
after surgery but incomplete PMA was not. All the patients
enrolled into our study would have had significant regional
remodeling in the inferoposterior wall with a great interpa-
pillary muscle distance. Therefore, complete PMA should
be considered even with a transvalvular approach to the
degree possible. Otherwise, alternative procedures with
new approaches, such as extracardiac and interventional
approaches, to the basal papillary muscles will be re-
quired for the improvement of the results.
Some concomitant procedures such as LVP could bias
the results of PMA because LVP causes radical changes of
LV geometry and functions, resulting in surgical reverse
remodeling of the LV. Although we found no significant
difference in mortality and the durability of repair between
those with complete PMA/LVP + and those with complete
PMA/LVP-, there was an inherent difference in ventricular
scar size, which could affect the outcomes. Thus, left ven-
triculoplasty might improve the results of those with large
ventricular scars and diminish the possible difference in
outcomes between those with complete PMA/LVP + and
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difference in mortality between those with incomplete
PMA and those with complete PMA/LVP- (log-rank P =
0.047). Therefore, concomitant left ventriculoplasty to
some extent influenced the outcomes of complete PMA
cases but did not significantly affect our conclusions. In
contrast, papillary muscle suspension could modify the ef-
fect of PMA. Especially with anterior suspension, further
improvement of posterior tethering could be expected. In
our study, however, papillary muscle suspension did not
demonstrate a significant effect on survival or the durabil-
ity of repair.
Limitations
There were several limitations to this study that should be
mentioned. First, the small sample size with a variety of
surgical procedures might have affected the statistical sig-
nificance. Because of the long study period with respect to
the sample size, a learning curve might affect the out-
comes. However, there was no significant difference in
mortality between those who underwent surgery in the
early (before 2006, N = 18) and late (after 2007, N = 27)
eras (log-rank P = 0.76). The rate of freedom from recur-
rence ≥2+ was also comparable between the groups (log-
rank P = 0.11). Second, we did not compare PMA and
annuloplasty alone because the baseline characteristics
and cardiac parameters in both populations were signifi-
cantly different in our cohort. Instead, we evaluated the
outcomes after PMA compared to the results of annulo-
plasty alone in previous reports. A future study comparing
PMA and annuloplasty with a larger sample size will help
further our understanding.
Conclusions
Complete PMA appears to be associated with a high sur-
vival rate and the durability of mitral valve repair for is-
chemic MR with severe LV remodeling. Approximation
of the basal papillary muscles with the surrounding LV
wall could be an important concept for the repair of is-
chemic MR.
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